Unleashing the potential of NOD- and toll-like agonists as vaccine adjuvants

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages 12294-12299

  Maisonneuve, Charles ^a   Bertholet, Sylvie ^b   Philpott, Dana J ^a   De Gregorio, Ennio ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

NLRP3; NOD1; NOD2; TLR4 alum

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CRYOPYRIN; IMMUNOLOGICAL ADJUVANT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VACCINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PATTERN RECOGNITION RECEPTOR;

ADAPTIVE IMMUNITY; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNITY, INNATE; NOD SIGNALING ADAPTOR PROTEINS; RECEPTORS, PATTERN RECOGNITION; TOLL-LIKE RECEPTORS; VACCINES;

EID: 84906658091     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400478111     Document Type: Review

References (82)

1. Gupta RK, et al. (1993) Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11(3):293-306. (Pubitemid 23061171)
2. Janeway CA, Jr. (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54(Pt 1):1-13.
3. Janeway CA, Jr., Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216.
4. Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16-34.
5. Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature 449(7164):819-826.
6. Pasare C, Medzhitov R (2004) Toll-like receptors and acquired immunity. Semin Immunol 16(1):23-26. (Pubitemid 38147430)
7. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085):808-812.
8. Magalhaes JG, et al. (2011) Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation. Proc Natl Acad Sci USA 108(36):14896-14901.
9. Cooney R, et al. (2010) NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16(1):90-97.
10. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136(7):2348-2357. (Pubitemid 16136806)
11. Croft M, Carter L, Swain SL, Dutton RW (1994) Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180(5):1715-1728. (Pubitemid 24328563)
12. Murphy KM, Reiner SL (2002) The lineage decisions of helper T cells. Nat Rev Immunol 2(12):933-944. (Pubitemid 37323214)
13. Magalhaes JG, et al. (2008) Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 181(11):7925-7935.
14. Agrawal S, et al. (2003) Cutting edge: Different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol 171(10):4984-4989. (Pubitemid 37432777)
15. Dillon S, et al. (2004) A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 172(8):4733-4743. (Pubitemid 38456394)
16. Fritz JH, et al. (2007) Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26(4):445-459. (Pubitemid 46604867)
17. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA (1996) The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6):973-983. (Pubitemid 26336801)
18. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5):637-650.
19. Qian C, Cao X (2013) Regulation of Toll-like receptor signaling pathways in innate immune responses. Ann N Y Acad Sci 1283:67-74.
20. De Gregorio E, d'Oro U, Bertholet S, Rappuoli R (2013) Vaccines. Fundamental Immunology (Lippincott Williams & Wilkins, Philadelphia), 7th Ed, pp 1032-1068.
21. Giannini SL, et al. (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34):5937-5949. (Pubitemid 44080367)
22. Tong NK, et al. (2005) Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 68(5):2298-2303. (Pubitemid 43117807)
23. Didierlaurent AM, et al. (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183(10):6186-6197.
24. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW (2008) CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 46(8):1310-1314. (Pubitemid 351589919)
25. Søgaard OS, et al. (2010) Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: A randomized, controlled trial. Clin Infect Dis 51(1):42-50.
26. Franchi L, et al. (2008) Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol 10(1):1-8. (Pubitemid 350239051)
27. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7(12):1250-1257. (Pubitemid 46111242)
28. Werts C, Girardin SE, Philpott DJ (2006) TIR, CARD and PYRIN: Three domains for an antimicrobial triad. Cell Death Differ 13(5):798-815.
29. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE (2014) NOD proteins: Regulators of inflammation in health and disease. Nat Rev Immunol 14(1):9-23.
30. Chamaillard M, et al. (2003) An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4(7):702-707. (Pubitemid 36874448)
31. Girardin SE, et al. (2003) Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300(5625):1584-1587. (Pubitemid 36682892)
32. Girardin SE, et al. (2003) Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 278(43):41702-41708. (Pubitemid 37310428)
33. Girardin SE, et al. (2005) Identification of the critical residues involved in peptidoglycan detection by Nod1. J Biol Chem 280(46):38648-38656. (Pubitemid 43853767)
34. Girardin SE, et al. (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278(11):8869-8872. (Pubitemid 36800360)
35. Inohara N, et al. (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278(8):5509-5512. (Pubitemid 36800790)
36. Mariathasan S, et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440(7081):228-232. (Pubitemid 43372102)
37. Martinon F, Agostini L, Meylan E, Tschopp J (2004) Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14(21):1929-1934. (Pubitemid 39464816)
38. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237-241. (Pubitemid 43372104)
39. Kool M, et al. (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205(4):869-882. (Pubitemid 351549884)
40. Li H, Willingham SB, Ting JP, Re F (2008) Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181(1):17-21.
41. Benko S, Philpott DJ, Girardin SE (2008) The microbial and danger signals that activate Nod-like receptors. Cytokine 43(3):368-373.
42. + efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38(6):1142-1153.
43. Sorbara MT, Girardin SE (2011) Mitochondrial ROS fuel the inflammasome. Cell Res 21(4):558-560.
44. Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469(7329):221-225.
45. Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59(4):1317-1325.
46. Adam A, Ciorbaru R, Ellouz F, Petit JF, Lederer E (1974) Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem Biophys Res Commun 56(3):561-567.
47. Lemesre JL, et al. (2005) Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23(22):2825-2840.
48. Lemesre JL, et al. (2007) Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial. Vaccine 25(21):4223-4234.
49. Parant MA, et al. (1980) Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs. Infect Immun 27(3):826-831. (Pubitemid 10147215)
50. Geddes K, Magalhães JG, Girardin SE (2009) Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov 8(6):465-479.
51. Hancock RE, Nijnik A, Philpott DJ (2012) Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 10(4):243-254.
52. Bahr GM (2003) Non-specific immunotherapy of HIV-1 infection: Potential use of the synthetic immunodulator murabutide. J Antimicrob Chemother 51(1):5-8.
53. Darcissac EC, et al. (2000) The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J Virol 74(17):7794-7802. (Pubitemid 30641624)
54. Rubino SJ, et al. (2013) Identification of a synthetic muramyl peptide derivative with enhanced Nod2 stimulatory capacity. Innate Immun 19(5):493-503.
55. Chedid L, Audibert F, Lefrancier P, Choay J, Lederer E (1976) Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci USA 73(7):2472-2475.
56. Migliore-Samour D, et al. (1979) Immunostimulating and adjuvant activities of a low molecular weight lipopeptide. Comptes rendus des seances de l'Academie des sciences. Serie D, Sciences Naturelles 289(5):473-476.
57. Adam A, Ellouz F, Ciorbaru R, Petit JF, Lederer E (1975) Peptidoglycan adjuvants: Minimal structure required for activity. Z Immunitatsforsch Exp Klin Immunol 149(2-4):341-348.
58. Kotani S, Watanabe Y, Shimono T, Narita T, Kato K (1975) Immunoadjuvant activities of cell walls, their water-soluble fractions and peptidoglycan subunits, prepared from various gram-positive bacteria, and of synthetic n-acetylmuramyl peptides. Z Immunitatsforsch Exp Klin Immunol 149(2-4):302-319.
59. Morefield GL, et al. (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13):1588-1595. (Pubitemid 40203396)
60. Kool M, et al. (2008) Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181(6):3755-3759.
61. Hornung V, et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9(8):847-856.
62. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198):1122-1126. (Pubitemid 351871731)
63. Franchi L, Núñez G (2008) The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38(8):2085-2089.
64. McKee AS, et al. (2009) Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183(7):4403-4414.
65. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9(4):287-293.
66. Marichal T, et al. (2011) DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 17(8):996-1002.
67. McKee AS, et al. (2013) Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci USA 110(12):E1122-E1131.
68. Dupuis M, et al. (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186(1):18-27. (Pubitemid 28285344)
69. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A (2008) The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180(8):5402-5412.
70. Calabro S, et al. (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29(9):1812-1823.
71. Ellebedy AH, et al. (2011) Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc Natl Acad Sci USA 108(7):2927-2932.
72. Seubert A, et al. (2011) Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA 108(27):11169-11174.
73. Vono M, et al. (2013) The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci USA 110(52):21095-21100.
74. Gavin AL, et al. (2006) Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314(5807):1936-1938. (Pubitemid 46026117)
75. Yoder A, et al. (2003) Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge. Infect Immun 71(7):3894-3900. (Pubitemid 36753712)
76. Kornbluth RS, Stone GW (2006) Immunostimulatory combinations: Designing the next generation of vaccine adjuvants. J Leukoc Biol 80(5):1084-1102. (Pubitemid 44646314)
77. Moingeon P, Haensler J, Lindberg A (2001) Towards the rational design of Th1 adjuvants. Vaccine 19(31):4363-4372. (Pubitemid 32718658)
78. Bagchi A, et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178(2):1164-1171. (Pubitemid 46095190)
79. Pavot V, et al. (2013) Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J Control Release 167(1):60-67.
80. Kruit WH, et al. (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31(19):2413-2420.
81. Ulloa-Montoya F, et al. (2013) Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31(19):2388-2395.
82. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82(5):488-496. (Pubitemid 39421058)